US Broker Ratings

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: Exploring a Potential Upside of 217.03% with Strategic Developments in Biotechnology

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) is rapidly emerging as a key player in the biotechnology sector, captivating investors with its strategic focus on innovative treatments..

Eton Pharmaceuticals (ETON): Analyst Ratings Signal 51.52% Upside for Investors

Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a burgeoning player in the healthcare sector specializing in treatments for rare diseases, is capturing the attention of investors with its..

Praxis Precision Medicines, Inc. (PRAX) Stock Analysis: Potential Upside and Market Dynamics

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is capturing significant attention in the biotechnology sector, particularly for its innovative approach to central nervous system (CNS) disorders. With..

Immatics N.V. (IMTX) Stock Analysis: A 60% Upside Potential in the Biotech Sector

Immatics N.V. (NASDAQ: IMTX), a promising player in the biotechnology sector, has captured the attention of investors with its groundbreaking focus on T cell redirecting immunotherapies..

CeriBell, Inc. (CBLL) Stock Analysis: Healthcare Innovator with a 154% Potential Upside

CeriBell, Inc. (CBLL), a medical device company specializing in innovative neurological care solutions, is capturing attention in the healthcare sector with its promising growth metrics and..

Simulations Plus, Inc. (SLP) Stock Analysis: A 47.91% Upside Potential in the Healthcare Sector

Simulations Plus, Inc. (NASDAQ: SLP) stands out in the healthcare sector, specifically within the health information services industry, for its innovative approach to drug discovery and..

uniQure N.V. (QURE) Stock Analysis: Navigating a 22% Potential Upside Amidst Gene Therapy Innovations

With a robust presence in the biotechnology sector, uniQure N.V. (QURE) is gaining attention in the investment community for its pioneering work in gene therapy. Headquartered..

Dianthus Therapeutics (DNTH) Stock Analysis: A 67.78% Potential Upside in the Biotechnology Sector

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is capturing the attention of investors with its impressive potential upside of 67.78%, as suggested by current analyst ratings. This clinical-stage..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: A Biotech with a Promising 228% Upside Potential

Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to developing small molecule and antibody therapies..

ArriVent BioPharma, Inc. (AVBP): Investor Outlook on a High-Upside Biotech Stock with 110% Potential Gain

ArriVent BioPharma, Inc. (NASDAQ: AVBP), a promising name in the biotechnology sector, has caught the attention of investors with its impressive potential upside of 110.07%. As..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Assessing a Potential 34.68% Upside in the Biotech Sector

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a name that has attracted attention within the biotechnology industry due to its innovative approach in the life sciences..

InMode Ltd. (INMD) Stock Analysis: Understanding the 5.11% Potential Upside in Medical Device Innovation

For investors with an eye on the medical device sector, InMode Ltd. (NASDAQ: INMD) presents an intriguing opportunity. Specializing in minimally invasive aesthetic medical products, InMode..

KalVista Pharmaceuticals (KALV) Stock Analysis: Exploring a 170% Upside Potential in the Biotech Sector

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a prominent player in the biotechnology industry, is on the radar of savvy investors due to its promising drug pipeline and..

Avadel Pharmaceuticals plc (AVDL) Stock Analysis: A 35.88% Upside Potential in the Biopharma Industry

Avadel Pharmaceuticals plc (NASDAQ: AVDL) presents a compelling opportunity for investors seeking exposure in the biopharmaceutical sector. With a focus on innovative treatments for narcolepsy, this..

Anavex Life Sciences Corp. (AVXL): Investor Outlook Highlights 276% Upside Potential

Anavex Life Sciences Corp. (NASDAQ: AVXL) stands out in the healthcare sector, particularly within the biotechnology industry, as a company with promising potential. Headquartered in New..

Embecta Corp. (EMBC) Investor Outlook: Unpacking the 16.88% Upside Potential

Embecta Corp. (NYSE: EMBC), a stalwart in the healthcare sector, has carved a niche in the medical instruments and supplies industry. With a market capitalization of..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Biotechnology Innovator with a 152% Potential Upside

Gyre Therapeutics, Inc. (GYRE), a dynamic player in the healthcare sector, is capturing investor attention with its promising pipeline of anti-inflammatory and anti-fibrotic drug developments. With..

Arbutus Biopharma (ABUS) Stock Analysis: A Promising 15% Upside Despite Earnings Challenges

Arbutus Biopharma Corporation (NASDAQ: ABUS), a clinical-stage biotechnology firm, is making significant strides in the healthcare sector. Specializing in innovative therapeutics for infectious diseases, the company..

Xeris Biopharma Holdings (XERS): Investor Outlook on Biotech’s Promising Growth Trajectory

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a dynamic player in the biotechnology industry, is capturing attention with its robust growth metrics and promising therapeutic portfolio. With..

Oculis Holding AG (OCS) Stock Analysis: Evaluating a Promising 112.98% Potential Upside in the Biotech Sector

Oculis Holding AG (NASDAQ: OCS), a clinical-stage biopharmaceutical pioneer based in Switzerland, is attracting significant attention in the biotechnology sector. With a robust market cap of..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds